Company Overview and News
11 IPOs are expected to price this week, making it another busy one, and totaling $3.4 billion in combined proceeds. A whopping six tech deals are pricing, including three from China. Chinese e-commerce giant Pinduoduo is the week's largest deal, raising $1.5 billion. US cybersecurity play Tenable should get the most attention - almost every enterprise software IPO with its profile has been a homerun.
DB BRY MS.PRE MS.PRF MS.PRG MS.PRA IPO MS.PRI SPOT MS.PRK MS IPOS SNAP
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
YUM AROC TCAP HYRE ABT CRM BXS BHC CHFC RGA CSCO TBIO UXIN CAH PKD MS HSY GWP SNAP NCMI FOX JCOM HOMB AMC GILD MNLO UTX SYF MDT CYS EXPE ACB GWPH EMHTF JNJ ALV VZ APHQF VNE LMT FB RF.PRB OLED RF.PRA STIM WFC.PRL NFLX WFC.PRJ BAX EHC SKX BAC WFC.PRT ZION OKE.WI WFC.PRR WFC.PRQ WFC.PRP WFC.PRO CYS.PRA CL WFC.PRN CYS.PRB FPBK TCCB OKE WFC.PRY TCCA INTC WFC.PRX WFC.PRW AGS WFC.PRV CBS UL WYNN EVER MA GSK FNSR TCDA UA FFKT NTGN HAS FNKO SBUX CAKE APTV TXN TBQBF XOM ACBFF TWX UAA MS.PRE RF RDI MS.PRF MS.PRG IMAX CNK MS.PRA GTES AMZN TWTR HMNY TWO EBAY BBT ARMO BAC CMA EYEN CRON BV TCC MDLZ CMG PFS MS.PRI BJ GOOGL MS.PRK LVS QCOM FOXA PFE LOVE WFCNP HAL PM HRB WWW GPC PYPL PAGS DLPH MCS PFG TWMJF RDIB AMCX WEED ACN DIS MCD ABT WFC WFC.WS QRVO MJN F SLDB BRY CMCSA K CGC SNPS EMH T MRK CVX FTSV SNE LITE MEDFF PZZA TILE
A fundamental reason people invest in small caps is their potential for better returns over longer periods. Small caps as an asset class tend to be more growth oriented, and thus investors may stand to gain more from allocating to small caps. However, higher volatility is inherent to U.S. small caps too.
RPUT MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA
Platform Specialty Products Corp (NYSE:PAH) Announcing the Sale of Arysta LifeScience and a New Chapter Conference Call July 20, 2018 8:30 AM ET
MS.PRI PAH MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA
Good morning, and welcome to State Street Corporation's Second Quarter of 2018 Earnings Conference Call and Webcast. Today's discussion is being broadcast live on State Street's website at investors.statestreet.com.
STT STT.PRC STT.PRE STT.PRD MS.PRE STT.PRG MS.PRF MS.PRG MS.PRA MS.PRI MS.PRK 3772 MS
Welcome to the presentation of our first half 2018 results. I propose to give you the highlights of this first half. Michel Favre will then detail our H1 2018 results, and I will close this presentation with our upgraded guidance.
DB MS.PRI SCGLF MS.PRK MS.PRE MS.PRF SCGLY MS.PRG GLE MS MS.PRA
The financial sector, which accounts for around one-fifth of the S&P 500 index, is now busy with Q2 earnings releases. The going is great so far, with five big banks crushing estimates on both lines and one reporting mixed results. The backdrop should favor the banks along with the course of oil, the stance taken by the Fed and the proposed policies of Trump (read: How Financial ETFs Look After Fed Stress Test).
WFCNP C.WSA MS.PRE WFC.PRL MS.PRF WFC.PRJ MS.PRG MS.PRA BAC WFC.PRT C.WS.B WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN C.WS.A C.PRP C.PRU WFC.PRY MS WFC.PRX WFC.PRW WFC.PRV C.PRS WFC WFC.WS BAC C VFH C.PRL IYG C.PRJ C.PRK C.PRG C.PRC MS.PRI C.PRPCL MS.PRK CGBBW
Perhaps it is because trading stocks can often mirror the thrill of winning big at the blackjack tables, or maybe it is because Las Vegas conjures images of the world’s most flashy brands and businessmen. Regardless of the reason, it is clear that gambling stocks are always among the most popular on Wall Street.
MS.PRI MS.PRK MS.PRE MS.PRF PENN MS.PRG MS RRR MS.PRA BYD
Greetings and welcome to the Kansas City Southern Second Quarter 2018 Earnings Call. At this time, all participants will be in a listen-only mode. A brief question-and-answer session will follow the formal presentation.
MS.PRI MS.PRK KSU.PR MS.PRE MS.PRF MS.PRG MS MS.PRA KSU
AUSTIN, Texas, July 20, 2018 (GLOBE NEWSWIRE) -- Jones Energy, Inc. (NYSE:JONE) (“Jones Energy” or “the Company”) today announced that its Board of Directors has hired Mr. Carl F. Giesler, Jr. as the Company’s new Chief Executive Officer effective July 23, 2018.
MS.PRI MS.PRK NOA JNEEP MS.PRE MS.PRF MS.PRG MS NOA MS.PRA JONE HRG
Good morning everyone, and welcome to the Citizens Financial Group Second Quarter 2018 Earnings Conference call. My name is Paul, and I'll be your operator today. [Operator Instructions] As a reminder, this event is being recorded.
CFG CFIN DB MS.PRI CIWV MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET